Biosciences investing resistant – but not immune – to global markets’ illnesses

Even in a recession, people get sick and need treatment, which is why biotech and pharmaceutical stocks have been seen as a relatively safe haven during the global financial crisis; life sciences venture capital actually rose 10% in Q3. Some notable recent deals include Israeli targeted-delivery spe...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Dandelion raises $30 million Series B as momentum for the geothermal heating and cooling system startup continues to grow

News Commentary | February 26, 2021

This marks Breakthrough Energy Ventures' first investment since announcing its $1 billion fund in January. Venture capital funding for geothermal startups has sharply fallen since its peak in 2010, but Dandelion joins Eavor as the second geothermal startup to raise funding in 2021, with the two ... Not part of subscription

Grab goes public in largest SPAC deal as merger talks with Gojek fail

News Commentary | April 08, 2021

Several rounds of rumors had suggested Grab and Gojek were nearing a merger. In a turn of events, Grab, Southeast Asia's largest startup, will likely raise more than $2 billion in funding by going public via the SPAC model through Altimeter. Financing from Ant Financial fell through along with the ... To read more, click here.

Helix announces $50 million Series C round, a significant dip from its Series A and B funding rounds

News Commentary | June 07, 2021

On the surface, Helix appears to have netted another significant investment, with a $50 million Series C round. Upon closer inspection, however, the amount is much lower than that of its Series A ($100 million) and Series B ($200 million) rounds. There is no indication if this is a down round, as ... Not part of subscription